Synthesis and biological activity of N-aryl-2-aminothiazoles: potent pan inhibitors of cyclin-dependent kinases.
暂无分享,去创建一个
David K Williams | John S Tokarski | J. Tokarski | F. Lee | S. D. Kimball | K. Webster | R. Misra | Hai-yun Xiao | David K. Williams | K. Kim | Songfeng Lu | Kristen A Keller | J. Mulheron | R. Batorsky | J. Sack | John S Sack | Raj N Misra | Hai-yun Xiao | Janet G Mulheron | S David Kimball | Kevin R Webster | Francis Y Lee | Songfeng Lu | Roberta Batorsky | Kyoung S Kim
[1] E. Sausville. Complexities in the development of cyclin-dependent kinase inhibitor drugs. , 2002, Trends in molecular medicine.
[2] L. Meijer,et al. Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds. , 1997, Journal of medicinal chemistry.
[3] A. Senderowicz,et al. Flavopiridol: the First Cyclin-Dependent Kinase Inhibitor in Human Clinical Trials , 2004, Investigational New Drugs.
[4] Punit Marathe,et al. Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities. , 2002, Journal of medicinal chemistry.
[5] E. Sausville,et al. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. , 1992, Journal of the National Cancer Institute.
[6] A. Huwe,et al. Small molecules as inhibitors of cyclin-dependent kinases. , 2003, Angewandte Chemie.
[7] M. Doyle,et al. Alkyl Nitrite-Metal Halide Deamination Reactions. 2. Substitutive Deamination of Arylamines by Alkyl Nitrites and Copper(II) Halides. A Direct and Remarkably Efficient Conversion of Arylamines to Aryl Halides , 1977 .
[8] E. Sausville,et al. Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Clinical Development , 2002, The Annals of pharmacotherapy.
[9] K. Webster,et al. The therapeutic potential of targeting the cell cycle. , 1998, Expert opinion on investigational drugs.
[10] E. Sausville,et al. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. , 1996, Cancer research.
[11] K. Webster,et al. Novel drugs targeting the cell cycle , 2000 .
[12] E. Schierenberg,et al. Cellular effects of olomoucine, an inhibitor of cyclin‐dependent kinases , 1995, Biology of the cell.
[13] T. Hunter,et al. Cyclins and cancer II: Cyclin D and CDK inhibitors come of age , 1994, Cell.
[14] J. Blow,et al. Inhibition of cyclin-dependent kinases by purine analogues. , 1994, European journal of biochemistry.
[15] E. Sausville,et al. Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy. , 1996, International journal of oncology.
[16] P. Ponath. Chemokine receptor antagonists: novel therapeutics for inflammation and AIDS. , 1998, Expert opinion on investigational drugs.
[17] C. Sherr. Cancer Cell Cycles , 1996, Science.
[18] Punit Marathe,et al. N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. , 2004, Journal of medicinal chemistry.
[19] K. Webster,et al. Chapter 14. Cell cycle kinases and checkpoint regulation in cancer , 2001 .
[20] E. Vokes,et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] B. D. Harris,et al. Reductive Amination of Aldehydes and Ketones with Sodium Triacetoxyborohydride. Studies on Direct and Indirect Reductive Amination Procedures(1). , 1996, The Journal of organic chemistry.